Strategies to modulate immune responses: a new frontier for gene therapy - PubMed (original) (raw)

Review

. 2009 Sep;17(9):1492-503.

doi: 10.1038/mt.2009.150. Epub 2009 Jul 7.

Affiliations

Review

Strategies to modulate immune responses: a new frontier for gene therapy

Valder R Arruda et al. Mol Ther. 2009 Sep.

Abstract

The success of gene therapy strategies to cure disease relies on the control of unwanted immune responses to transgene products, genetically modified cells and/or to the vector. Effective treatment of an established immune response is much harder to achieve than prevention of a response before it has had a chance to develop. However, preventive strategies are not always effective in avoiding immune responses, thus the use of drugs to induce immunosuppression (IS) is required. The growing discovery of novel drugs provides a conceptual shift from using generalized, moderately intensive immunosuppressive regimens towards a refined approach to attain the optimal balance of naive cells, effector cells, memory cells, and regulatory cells, harnessing the natural tolerance mechanisms of the body. We review several strategies based on transient IS coupled with gene therapy for sustained immune tolerance induction to the therapeutic transgene.

PubMed Disclaimer

Figures

<b>Figure 1</b>

**Figure 1

Mechanisms of T-cell regulation. APC, antigen-presenting cell.

<b>Figure 2</b>

**Figure 2

T- and B-cell activation. Overview of the major proteins and pathways involved in (a) T-cell activation by antigen-presenting cells (APCs) and (b) B-cell activation by CD4 T helper cells. CTL, cytotoxic T lymphocyte; IFN, interferon; IL, interleukin; TOR, target-of-rapamycin.

Similar articles

Cited by

References

    1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715–2729. - PubMed
    1. Kamradt T., and , Mitchison NA. Tolerance and autoimmunity. N Engl J Med. 2001;344:655–664. - PubMed
    1. Vignali DA, Collison LW., and , Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–532. - PMC - PubMed
    1. Thomas CE, Ehrhardt A., and , Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346–358. - PubMed
    1. Bessis N, GarciaCozar FJ., and , Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11 Suppl 1:S10–S17. - PubMed

Publication types

MeSH terms

LinkOut - more resources